Patents Examined by Kimberly Ballard
  • Chemical reprogramming of human glial cells into neurons with small molecule cocktail
    Patent number: 10253293
    Abstract: Provided are compositions, articles and methods that relate to promoting neurogenesis or neuroregeneration in mammalian nervous system. Embodiments relate to use of groups of compounds that contain Crizotinib (Cri), Flurbiprofen, Lithium Chloride (Li), Vitamin C (VC), Ceritinib (Cer) or Pirfenidone (PFD). In certain implementations glial cells are converted into functional neurons.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: April 9, 2019
    Assignee: The Penn State Research Foundation
    Inventors: Gong Chen, Lei Zhang, Jiuchao Yin, Ningxin Ma
  • Composition comprising a culture solution of mesenchymal stem cells for the treatment of neural diseases
    Patent number: 10238692
    Abstract: Provided are a pharmaceutical composition for prevention and treatment of a neural disease including at least one selected from the group consisting of mesenchymal stem cells (MSCs), a culture solution of the MSCs, activin A, PF4, decorin, galectin 3, GDF15, glypican 3, MFRP, ICAM5, IGFBP7, PDGF-AA, SPARCL1, thrombospondin-1, WISP1, progranulin, IL-4, a factor inducing expression thereof, and any combination thereof, and a method therefor.
    Type: Grant
    Filed: November 16, 2009
    Date of Patent: March 26, 2019
    Assignee: MEDIPOST CO., LTD
    Inventors: Yoon-Sun Yang, Won II Oh, Jong Wook Chang, Ju Yeon Kim
  • Specific amyloid beta binding peptides and the use of same for treating and diagnosing alzheimer's dementia
    Patent number: 10239923
    Abstract: Peptides specifically binding amyloid beta and to methods of treating and diagnosing Alzheimer's dementia using such peptides are provided.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: March 26, 2019
    Assignee: FORSCHUNGSZENTRUM JUELICH GMBH
    Inventors: Dieter Willbold, Stephan Rudolph, Janine Kutzsche, Susanne Aileen Funke
  • Methods, compositions, diagnostics and assays for the treatment of Alzheimer's disease
    Patent number: 10233222
    Abstract: The invention provides compounds for the treatment of Alzheimer's disease, methods for the use of such compounds, assays for the identification of such compounds, and methods for diagnosis of Alzheimer's disease and diagnostic kits. Methods of marketing compounds are also disclosed. In one aspect, the disclosure provides a compound for the diagnosis or treatment of Alzheimer's disease wherein the compound is a modulator that inhibits the disruption by amyloid ? of a complex comprising synaptophysin and/or synaptobrevin. In another aspect, the disclosure provides a pharmaceutical composition comprising the compounds disclosed herein in an amount sufficient to treat Alzheimer's disease in a subject. In another aspect, the disclosure provides a diagnostic composition comprising the compound disclosed herein.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: March 19, 2019
    Assignees: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE, AMIDEBIO, LLC
    Inventors: Michael H. B. Stowell, Mikhail Plam
  • Method of inhibiting microglial cell migration and treating traumatic brain injury
    Patent number: 10213480
    Abstract: Disclosed herein is a method of inhibiting microglial cell migration in the brain of a mammalian subject in need thereof, including subjects suffering from the symptoms of traumatic brain injury (TBI) and subjects suffering from a hematoma in the brain comprising administering an effective amount streptolysin O (SLO) wherein microglial migration is inhibited providing therapeutic benefits to subjects suffering from diseases characterized by microglial cell migration and activation.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: February 26, 2019
    Assignee: BEECH TREE LABS, INC.
    Inventor: John McMichael
  • Methods for estimating prion concentration in fluids and tissue by quantitative PMCA
    Patent number: 10215763
    Abstract: The present embodiments disclose methods for estimating PrPSc concentration in fluids and tissues by quantitative PMCA.
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: February 26, 2019
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Claudio Soto, Baian Chen, Rodrigo Morales
  • Monoclonal antibodies against amyloid beta protein and uses thereof
    Patent number: 10208109
    Abstract: The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.
    Type: Grant
    Filed: July 21, 2011
    Date of Patent: February 19, 2019
    Assignees: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO KG
    Inventors: Heinz Hillen, Stefan Barghorn, Boris Labkovsky, Ulrich Ebert, Andreas R. Striebinger, Patrick Keller
  • Ameliorating nervous systems disorders
    Patent number: 10206953
    Abstract: The present disclosure provides methods for the treatment of a mammal having a neurological condition, disease, or injury. The methods involve increasing the number of functional GABAergic interneurons at or near the site of the neurological disease, injury, or condition.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: February 19, 2019
    Assignee: The Regents of the University of California
    Inventors: Arnold Kriegstein, John L. R. Rubenstein, Scott C. Baraban, Arturo Alvarez-Buylla
  • Treatment agent for cognitive impairment induced by amyloid beta-protein, therapeutic agent for alzheimer's disease, and treatment method and pathological analysis method related to these
    Patent number: 10206979
    Abstract: Disclosed is a method of treatment for anti-Alzheimer's disease based on an action mechanism associated with amyloid ? protein, which action mechanism is different from conventional action mechanisms. The treatment Alzheimer's disease uses a therapeutic agent for cognitive impairment induced by amyloid ? protein, which therapeutic agent comprises a peptide having the amino acid sequence represented by SEQ ID NO:1 or a peptide similar to this peptide, especially a peptide containing the amino acid sequence represented by SEQ ID NO:2, which is a partial sequence of SEQ ID NO:1. VLSSQQFLHRGHQPPPEMAGHSLASSHRNSMIPSAAT (SEQ ID NO:1) HRGHQPPPEMA (SEQ ID NO:2).
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: February 19, 2019
    Assignees: NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventors: Tsuyoshi Inoue, Toshiharu Suzuki, Saori Ban
  • Peptides
    Patent number: 10208087
    Abstract: The present invention relates to dual-site BACE1 inhibitors, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: February 19, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Per-Ola Freskgard, Eric A. Kitas
  • Lyophilized formulation of TAT-NR2B9C with acetylation scavenger
    Patent number: 10206878
    Abstract: The present invention provides lyophilized formulations of active agents, particularly of TAT-NR2B9c including histidine, trehalose and lysine. TAT-NR2B9c has shown promise for treating stroke, aneurysm, subarachnoid hemorrhage and other neurological or neurotraumatic conditions. Such formulations are stable at ambient temperature thus facilitating maintenance of supplies of such a formulation in ambulances for administration at the scene of illness or accident or in transit to a hospital.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: February 19, 2019
    Assignee: NoNO Inc.
    Inventors: Jonathan David Garman, Frieder Hofmann
  • Biomarkers and differential diagnosis of alzheimer's disease and other neurodegenerative disorders
    Patent number: 10203342
    Abstract: The present invention relates to biomarkers and diagnostic and prognostic methods for Alzheimer's disease and other neurodegenerative disorders. The invention also provides compositions for detecting the biomarker as well as compositions and methods useful for treating Alzheimer's disease and other neurodegenerative disorders.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: February 12, 2019
    Assignee: NANOSOMIX, INC.
    Inventor: Edward J. Goetzl
  • Methods and compositions for increasing ?-L-iduronidase activity in the CNS
    Patent number: 10202467
    Abstract: Provided herein are methods and compositions for treating a subject suffering from a deficiency in ?-L-Iduronidase in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an ?-L-Iduronidase. A therapeutically effective systemic dose is based on the specific CNS uptake characteristics of human insulin receptor antibody-?-L-Iduronidase fusion antibodies as described herein.
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: February 12, 2019
    Assignee: ARMAGEN, INC.
    Inventors: William M. Pardridge, Ruben J. Boado
  • Na1.7 antibodies and methods of using the same
    Patent number: 10202450
    Abstract: Disclosed herein is an antibody that binds to a voltage sensor paddle (VSP) of Nav1.7. Also disclosed herein are methods of treating pain, itch, neurogenic inflammation, or cough in a subject in need thereof. The methods include administrating the antibody to the subject.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: February 12, 2019
    Assignee: Duke University
    Inventors: Seok-Yong Lee, Ru-Rong Ji
  • Boosting Treg cells for treating Alzheimer disease and related disorders
    Patent number: 10183061
    Abstract: The present invention relates to the boosting of Treg cells for the treatment of Alzheimer's disease and related disorders.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: January 22, 2019
    Assignees: ICM (INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE), APHP (ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSERM (INSTITUT NATIONAL DE LA RECHERCHE MEDICALE), SORBONNE UNIVERSITE
    Inventors: Guillaume Dorothee, Eliane Piaggio, Dylla Ait Ahmed, Pierre Aucouturier
  • Specific A-beta species-binding peptides for the therapy and/or diagnosis of Alzheimer's dementia
    Patent number: 10174097
    Abstract: The invention relates to peptides binding specifically to Abeta species for treating and/or diagnosing Alzheimer's disease.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: January 8, 2019
    Assignee: Forschungszentrum Juelich GmbH
    Inventors: Dieter Willbold, Janine Kutzsche, Antonia Klein
  • Anti-mGluR2 conformational single domain antibodies and uses thereof
    Patent number: 10174115
    Abstract: The present invention relates to anti-metabotropic glutamate receptor subtype 2 (mGluR2) conformational single domain antibodies and uses thereof in particular in the therapeutic and diagnostic field.
    Type: Grant
    Filed: July 3, 2015
    Date of Patent: January 8, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, UNIVERSITÉ D'AIX MARSEILLE, UNIVERSITE DE MONTPELLIER, CISBIO BIOASSAYS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITÉ PARIS-SUD
    Inventors: Daniel Baty, Jean-Philippe Pin, Patrick Chames, Damien Nevoltris, Philippe Rondard, Pauline Scholler, Gérard Mathis
  • Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications
    Patent number: 10174105
    Abstract: Use of a variable fragment (VHH antibody) of a camelid single-chain antibody for the preparation of a peptide vector for delivering a substance of interest across the blood-brain barrier or into a cell.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: January 8, 2019
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Francois Rougeon, Pierre Lafaye, Jean-Pierre Bourgeois
  • Methods of maintaining, expanding and differentiating neuronal subtype specific progenitors
    Patent number: 10160950
    Abstract: Methods for expanding proliferating populations of neuronal subtype-specific progenitors and creating substantially pure populations of motor neurons are provided herein. In particular, the present invention provides methods for maintaining the unique gene profile and differentiation potential of neuronal subtype-specific progenitors, such as motor neuron progenitors and hindbrain serotonergic neural progenitors.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: December 25, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Su-Chun Zhang, Zhongwei Du
  • Antibodies to ?-synuclein and uses thereof
    Patent number: 10160800
    Abstract: The invention provides antibodies that specifically bind human ?-synuclein with a high affinity and reduces ?-synuclein spreading in vivo, recombinant polypeptides comprising said antibodies or antigen-binding fragment thereof and methods for generating such polypeptides, as well as compositions and methods for generating ?-synuclein antibodies, and methods of using ?-synuclein antibodies for the treatment of diseases of the central nervous system, in particular alpha-synucleinopathies.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: December 25, 2018
    Assignee: MedImmune Limited
    Inventors: Darren Schofield, Michael Perkinton, Lorraine Irving, George Thom